Primus In News
Tarnished by cough syrup deaths, India’s pharma industry tries to look beyond the stupor
21-07-2023
Nilaya Varma, Co-Founder and CEO of Primus Partners shares his views on the impact of the COVID-19 pandemic and the Russia-Ukraine war on vaccine exports from India, especially to African and Commonwealth of Independent States (CIS) countries. In addition, he stresses that the increasing cost of raw materials and the withdrawal of GST exemption has exacerbated challenges for Indian pharma companies. Read Now!
Explore Related Insights
- Celebrating excellence in India’s Infrastructure: Winners for Build India Infra Awards 2025 announced
- Could Go First's bankruptcy hamstring India's aviation sector again?
- Indian IT sector lags in global RPE standards, yet digital shift signals growth potential
- How Rajasthan is creating long-term income-generating opportunities for rural women